Trade Summary

6 months ago, Siegall Clay B, serving as Pres, CEO at Immunome Inc. (IMNM), purchased 7,278 shares at $20.48 per share, for a total transaction value of $149,053.00. Following this transaction, Siegall Clay B now holds 660,525 shares of IMNM.

This purchase represents a 1.00% increase in Siegall Clay B's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, December 19, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 22, 2025 at 7:38 AM ET, 3 days after the trade was made.

Immunome Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.